Aenova to purchase the Temmler Group
Will enable Aenova to consolidate its leading market position in Europe
Aenova has agreed to buy the Temmler Group, a contract pharmaceutical manufacturer based in Marburg, Germany, for an undisclosed sum.
The Temmler Group is a full-service provider for pharmaceutical contract manufacturing. It has seven production sites in Germany, Switzerland, Italy and Ireland, employing around 1,000 people. Turnover is at around €170m.
The firm offers a complete range of contract manufacturing services for solid, semi-solid and liquid dosage forms. It also develops and sells its own pharmaceutical products.
The Aenova Group, headquartered in Pähl near Munich, is a leading provider of services for the development, manufacturing and commercialisation of solid dosage forms, such as soft gelatin and hard capsules, conventional and film-coated tablets, dragées and effervescent tablets.
The firm was formed following the merger of Dragenopharm and Swiss Caps and is now owned by private equity firm BC Partners. It has seven production sites in Germany, Switzerland, France, Romania and the US and employs around 1,600 people. The firm’s annual turnover is around €280m.
The transaction is conditional on the approval of the relevant competition authorities and is likely to be finalised at the end of this year.
Heiner Hoppmann, CEO of the Aenova Group, said: ‘The acquisition of the Temmler Group allows us to extend our position as European market leader. The portfolios of the two companies complement one another perfectly, as the Temmler Group produces dosage forms such as salves, gels and drops, and is involved in new service segments, including the manufacture of clinical trial materials, distribution logistics and licensing.’
Werner Schneider, CEO of the Temmler Group, said the move ‘gives Temmler an excellent perspective for the future and for the ongoing development of the business’.
The equity for the transaction is being provided by funds advised by BC Partners.